TrialBlood advances2022

Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.

Joselle Cook et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.